Fufang Lvbing Nalin Xiuji Xin Jiaonang (复方氯丙那林溴己新胶囊)复方氯丙那林溴己新胶囊
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 苏州第三制药厂有限责任公司Chinese legal name: 苏州第三制药厂有限责任公司
主要成分Active Ingredients
- 氯丙那林Lvbing Nalin
药物知识说明
氯丙那林是一种在国家药监局注册认定的药品。该药品含有氯丙那林-c4204b86等成分。
该药品关联的活性成分包括：氯丙那林Lvbing Nalin。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：苏州第三制药厂有限责任公司Chinese legal name: 苏州第三制药厂有限责任公司。
您可以探索含有相同成分的其他药品：氯丙那林-c4204b86成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 复方氯丙那林溴己新胶囊) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 氯丙那林Lvbing Nalin.
Manufacturers recorded for this product: 苏州第三制药厂有限责任公司Chinese legal name: 苏州第三制药厂有限责任公司.
Explore other medicines containing the same ingredient: 氯丙那林 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 复方氯丙那林溴己新胶囊Recorded Chinese name: 复方氯丙那林溴己新胶囊
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 0.15g*100s0.15 g × 100s
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 苏州第三制药厂有限责任公司Chinese legal name: 苏州第三制药厂有限责任公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H32025522
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H32025522
Manufacturer
Chinese legal name: 苏州第三制药厂有限责任公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H32025522
生产企业
苏州第三制药厂有限责任公司(国产)
适应症
本品用于支气管哮喘、哮喘型支气管炎、慢性支气管炎合并肺气肿，可止喘，并改善肺功能。
用法用量
口服：每次5～10mg，1日3次。预防夜间发作可于睡前加服5～10mg。气雾吸入：每次6～10mg。
不良反应
用药初期1～3日，个别患者可见心悸、手颤、口干、头痛及胃肠道反应。继续用药，多能自选消失。
禁忌
对本品过敏患者禁用。
注意事项
1、用药初期1～3日，个别患者可见心悸、手指震颤、头痛及胃肠道反应，继续服药，多能自行消失；
2、心律失常、高血压病及甲状腺功能亢进患者慎用。
贮藏
遮光，密闭保存。
规格
0.15g*100s
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.